As previously mentioned, the anti-CCR4 antibody mogamulizumab, which is being tested in T-cell lymphomas, might similarly counteract microenvironment formation and prove of therapeutic relevance in selected cHL patients [29]. This evidence concerns the gene CCR4 and classic Hodgkin lymphoma.